Mimedx Group, Inc.
MDXG Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 23, 2026
$3.91
KIRA · Stoqly’s AI analyst, in plain words
- Mimedx Group, Inc. had $419M of revenue in fiscal 2025, up 20.0% on the year before. Over five years, revenue changed +11.0% a year on average.
- Its operating margin was 15.3%, down 1.6 pts: of every 100 in sales, about 15 is left after running the business.
- Mimedx Group, Inc. made $48.6M of net profit in fiscal 2025.
- Mimedx Group, Inc. returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 0.5%.
- Mimedx Group, Inc. has $148M more cash than debt.
Market cap
$578M
P/E
97.8x
Revenue
$419M
Net income
$48.6M
Free cash flow
—
Operating margin
15.3%
Mimedx Group, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+20.0%
Yes. Sales grew 20.0% last year.
Does it make a profit?
11.6%
Yes. It keeps 11.6% of every sale as profit.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
97.8x
One share costs 97.8 times its yearly profit per share.
What Mimedx Group, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 25, 2026
- Legal name
- MIMEDX GROUP, INC.
- CIK
- 0001376339
Mimedx Group, Inc. · MDXG
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $242M | $268M | $321M | $349M | $419M |
| Revenue growth | −2.5% | 10.7% | 20.0% | 8.5% | 20.0% |
| Net interest income | −$5.0M | −$5.0M | −$6.5M | — | — |
| Gross margin | 83.6% | 82.0% | 83.0% | 82.8% | 82.6% |
| Operating margin | −2.9% | −5.5% | 11.5% | 16.9% | 15.3% |
| Net income | −$10.3M | −$30.2M | $58.2M | $42.4M | $48.6M |
| Net margin | −4.2% | −11.3% | 18.1% | 12.2% | 11.6% |
| Diluted EPS | −$0.15 | −$0.33 | $0.37 | $0.28 | $0.32 |
| Cash | |||||
| Cash from operations | −$2.0M | −$17.9M | $26.8M | $66.2M | $74.0M |
| Capital expenditure | $3.2M | $1.5M | $2.0M | — | — |
| Free cash flow | −$5.2M | −$19.4M | $24.8M | — | — |
| FCF margin | −2.1% | −7.2% | 7.7% | — | — |
| Share buybacks | $0.0M | $0.0M | $9.5M | $0.0M | $0.0M |
| Share count change | 1.9% | 2.3% | 29.3% | 2.1% | 0.5% |
| Debt and strength | |||||
| Cash and short-term investments | $87.1M | $66.0M | $82.0M | $104M | $166M |
| Debt incl. finance leases | $50.2M | $50.1M | $50.1M | $19.0M | $18.0M |
| Shareholders' equity | $0.1M | −$18.0M | $143M | $193M | $257M |
| Net debt / EBITDA | — | — | −0.8x | −1.3x | −1.9x |
| Current ratio | 3.5x | 3.1x | 3.6x | 4.2x | 4.3x |
| Interest coverage | — | −2.9x | 5.6x | 14.9x | 35.8x |
| Returns and quality | |||||
| Return on capital | — | — | 33.5% | 40.1% | 43.2% |
| Return on equity | — | — | 93.4% | 25.3% | 21.6% |
| Return on tangible equity | — | — | 49.3% | 26.2% | 21.8% |
| Piotroski F-score | 4 | 2 | 6 | 5 | 5 |
| Altman Z'' | 0.6 | −1.0 | 4.0 | 6.9 | 8.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.4M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Mimedx Group, Inc. · MDXG
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.91 a share, the company is worth $578M: 97.8 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001376339). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.